Roivant Sciences
ROIV
Roivant Sciences (ROIV) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- −$0.33
- EPS estimate
- −$0.31
- EPS surprise
- −6.80%
- Revenue surprise
- −12.58%
- Revenue
- $1.4M
- Revenue estimate
- $1.6M
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Aug 6, 2026 | −$0.31 | −$0.33 | −6.80% | $1.4M | SEC |
| Q4 2026 | May 20, 2026 | −$0.29 | $0.28 | +196.51% | $2.5M | SEC |
| Q3 2026 | Feb 6, 2026 | −$0.30 | −$0.17 | +43.41% | $2.0M | SEC |
| Q2 2026 | Nov 10, 2025 | −$0.32 | −$0.20 | +36.87% | $1.6M | SEC |
| Q1 2026 | Aug 11, 2025 | −$0.25 | −$0.25 | −0.84% | $2.2M | SEC |
| Q4 2025 | May 29, 2025 | −$0.26 | −$0.29 | −10.06% | $7.6M | SEC |
| Q3 2025 | Feb 10, 2025 | −$0.25 | $0.23 | +190.95% | $9.0M | SEC |
| Q2 2025 | Nov 12, 2024 | −$0.25 | −$0.31 | −25.51% | $4.5M | SEC |
| Q1 2025 | Aug 8, 2024 | −$0.24 | $0.12 | +149.32% | $55.1M | SEC |
| Q4 2024 | May 30, 2024 | −$0.26 | −$0.19 | +28.14% | $28.9M | SEC |
| Q3 2024 | Feb 13, 2024 | −$0.31 | $6.03 | +2051.46% | $37.1M | SEC |
| Q2 2024 | Nov 13, 2023 | −$0.29 | −$0.26 | +8.78% | $37.1M | SEC |
| Q1 2024 | Aug 14, 2023 | −$0.28 | −$0.23 | +19.98% | $21.6M | SEC |
| Q4 2023 | Jun 28, 2023 | −$0.36 | −$0.22 | +39.43% | $27.4M | SEC |
| Q3 2023 | Feb 13, 2023 | −$0.39 | −$0.41 | −4.82% | $17.1M | SEC |
| Q2 2023 | Nov 14, 2022 | −$0.38 | −$0.29 | +22.73% | $12.5M | SEC |
| Q1 2023 | Aug 15, 2022 | −$0.32 | −$0.48 | −50.19% | $4.3M | SEC |
| Q4 2022 | Jun 28, 2022 | −$0.31 | −$0.27 | +11.38% | $9.2M | SEC |
| Q3 2022 | Feb 14, 2022 | −$0.25 | −$0.41 | −61.04% | $24.3M | SEC |
| Q2 2022 | Nov 15, 2021 | −$0.33 | −$0.32 | +1.57% | $14.0M | — |
Quarterly revenue
Frequently asked questions
When did Roivant Sciences (ROIV) last report earnings?
Roivant Sciences last reported on Aug 6, 2026, covering fiscal Q1 2027.
Did ROIV beat earnings estimates?
No. Roivant Sciences reported EPS of −$0.33 for Q1 2027 against a −$0.31 estimate — a 6.80% miss.
How much revenue did ROIV report last quarter?
Roivant Sciences reported $1.4M in revenue for Q1 2027, against a consensus estimate of $1.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.